

1 **Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2**
2 **vaccine, KD-414, in healthy adult participants: a non-randomized, open-label**
3 **phase 2/3 clinical study in Japan**

4

5 Keishi Kido¹, Kayo Ibaragi¹, Mitsuyoshi Tanishima¹, Yosuke Muramoto¹, Shun Nakayama¹, Kohei
6 Ata¹, Kenshi Hayashida¹, Hideki Nakamura¹, Yasuhiko Shinmura¹, Yoshiaki Oda¹, Masafumi Endo¹,
7 Kengo Sonoda¹, Yuji Sasagawa², Yasuhiro Iwama², Kohji Ueda³, Takayuki Matsumoto¹

8 ¹KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan

9 ²Meiji Seika Pharma Co., Ltd., Tokyo, Japan

10 ³Professor emeritus, Kyushu University, Fukuoka, Japan

11

12 **CORRESPONDENCE**

13 Keishi Kido

14 KM Biologics Co., Ltd (KM Biologics), 869-1298 Kumamoto, Japan.

15 Email: kido@kmbiologics.com

16

17

18 **Abstract:**

19 **Background:** In the prolonged COVID-19 pandemic, there remains a high need for
20 the development of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
21 2) vaccine that can be used more safely and effectively to prevent the disease onset
22 or severe disease. To satisfy such unmet need, we are currently developing the
23 inactivated whole particle SARS-CoV-2 vaccine (KD-414) and conducted a phase 2/3
24 study in healthy adults in Japan to accumulate more immunogenicity and safety data
25 of KD-414 using the dose selected based on the results of the phase 1/2 study.

26 **Methods:** In an open-label uncontrolled phase 2/3 study, adults aged 18 years or older
27 without a history of COVID-19 or COVID-19 vaccination received two intramuscular
28 doses of KD-414 at a 28-day intervals, followed by one intramuscular dose 13 weeks
29 after the second dose as the primary immunization. Safety data were collected after
30 the first dose of KD-414 in all participants to evaluate the safety profile. In
31 predetermined immunogenicity analysis subjects, the neutralizing antibody titers
32 against the pseudovirus SARS-CoV-2 (Wuhan) before the first vaccination and after
33 each vaccination with KD-414 were evaluated.

34 **Results:** A total of 2500 adults aged 18 years or older were enrolled; 2474 of them
35 received the vaccination up to the second dose, and 2081 completed the third
36 vaccination. Regarding the safety, no deaths or serious adverse reactions were
37 recorded from the first vaccination until 28 days after the third vaccination with KD-
38 414. The incidence of adverse reactions (number of participants with onsets/number
39 of participants in the safety analysis set) was 80.6% (2015/2500). Adverse reactions
40 with an incidence of 10% or more included injection site pain, malaise, headache,

41 injection site erythema, myalgia, and injection site induration. A total of 11 events of
42 grade 3 or higher adverse reactions that prevented daily activities in 9 participants.
43 There was no increasing tendency in the incidence of adverse reactions responding to
44 the vaccinations. To evaluate immunogenicity, 295 first comers enrolled from five age
45 ranges were allocated to the immunogenicity analysis subjects; 291 participants
46 received the vaccination up to the second dose, and 249 participants completed the
47 third vaccination. The geometric mean titers (95% confidence interval [CI]) of
48 neutralizing antibody titers against pseudovirus SARS-CoV-2 (Wuhan) 28 days after
49 the second vaccination and 28 days after the third vaccination with KD-414 were
50 139.6 (118.9 - 164.0) and 285.6 (244.3 - 334.0), respectively, showing an
51 approximately two-fold increase after the third vaccination compared to that after the
52 second vaccination. The geometric mean titers (95% CI) of neutralizing antibody titers
53 after the third vaccination were 327.6 (269.8 - 397.9), 272.2 (211.5 - 350.4) and 128.0
54 (51.6 - 317.7) in participants aged 18 to 40 years, 41 to 64 years, and 65 years or older,
55 respectively, showing an age-dependency.

56 **Conclusion:** This study confirmed the favorable safety profile of KD-414 as a result
57 of three vaccinations of KD-414 administered to over 2000 healthy Japanese
58 participants aged 18 years or older. There were no particular differences in the types
59 and incidences of adverse reactions between vaccinations, and no tendency of an
60 increase in adverse reactions with an increase in the number of vaccinations. Similar
61 to the phase 1/2 study, neutralizing antibody responses appeared to be age-dependent
62 and the highest titers were observed in the age group of 18 - 40 years. A phase 3 study
63 in adults aged 18 - 40 years (jRCT2031210679) and a phase 2/3 study in children aged

64 6 months - 18 years (jRCT2031220032) are currently ongoing.

65 **Introduction**

66 COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-
67 CoV-2), which was identified in December 2019 in Wuhan, Hubei Province, China. Thereafter, a
68 Public Health Emergency of International Concern (PHEIC) was declared by the World Health
69 Organization (WHO) on January 30, 2020 and a global pandemic was declared on March 11, 2020 ¹.
70 As of September 9, 2022, 610 million cases of SARS-CoV-2 infection have been reported, resulting
71 in 6.5 million deaths, so vaccine development against COVID-19 remains a significant global
72 challenge ².

73 At present, vaccines against COVID-19, including inactivated vaccines, DNA vaccines and mRNA
74 vaccines, viral vector vaccines, recombinant protein vaccines, etc. have been developed in the United
75 States, the United Kingdom, China, and other countries around the world. In Japan, five products of
76 mRNA vaccines, a viral vector vaccine, and a recombinant protein vaccine have been approved as of
77 September 2022 ³⁻⁷. However, most of them are imported and there are concerns regarding adverse
78 reactions associated with new modality, such as myocarditis and thrombosis with thrombocytopenia
79 syndrome ⁸⁻¹¹. Because of that, booster shots (a third dose and fourth dose) and primary vaccination
80 in children who require higher safety are not progressing. It is important to secure sufficient amounts
81 of vaccines against SARS-CoV-2 in Japan for future emergencies and, similar to seasonal influenza
82 vaccines, these vaccines will be continuously required in the future. Thus, domestic vaccines with an
83 effectiveness and high safety are needed.

84 KD-414 is a purified, inactivated, whole-virus SARS-CoV-2 vaccine, which is a modality that has
85 been effective as multiple infectious disease vaccines and has an established safety. The manufacturing
86 method is described in a previous report ¹².

87 In the phase 1/2 study of KD-414, safety and immunogenicity were evaluated after two intramuscular
88 vaccinations at three different doses of KD-414 which have different active ingredients (converted to
89 protein amount): product L (2.5 µg/dose), product M (5 µg/dose), and product H (10 µg/dose). The
90 results showed that the investigational product was well tolerated at all the dose levels, and the
91 neutralizing antibody titer was the highest in the product H (10 µg/dose) group ¹². Therefore, we

92 decided to use product H (10 µg/dose) in the late-stage clinical studies of KD-414. However, although
93 the preventive effect of the novel corona vaccine against the onset has been shown to correlate highly
94 with the neutralizing antibody levels ¹³, the threshold of neutralizing antibody titers required for
95 prevention has not yet been established. Therefore, it is important to evaluate the vaccination regimen
96 of the three doses as a primary series that can induce higher neutralizing antibody titers.
97 Here, we report safety and immunogenicity findings from the phase 2/3 study conducted to evaluate
98 the safety and immunogenicity of three doses of KD-414 in adults aged 18 years or older to accumulate
99 more safety and immunogenicity data of KD-414 using the dose selected in the phase 1/2 study.

100

101 **Materials and Methods:**

102 **Study design, and participants**

103 This multicenter, open-label, and uncontrolled study was conducted at 12 sites in Japan. The target
104 number of participants was 2000, with healthy Japanese participants aged 18 years or older.

105 The study excluded participants with a history of COVID-19 or vaccination against COVID-19,
106 including unapproved vaccines. In addition, participants confirmed to be infected with SARS-CoV-2
107 during the study were withdrawn from the study. During the trial, the investigator instructed the
108 participants to undergo laboratory tests, including PCR, if the participant experienced fever, chills,
109 cough, shortness of breath, and/or dyspnea for at least 24 hours or if the participant experienced
110 malaise, myalgia, arthralgia, headache, dysgeusia, smell disorder, sore throat, stuffy nose, runny nose,
111 nausea, vomiting, and diarrhea for at least 48 hours.

112 This study was reviewed and approved by the institutional review boards (IRBs) of all the institutions.
113 Written informed consent was obtained from all participants before the screening. In addition, the
114 study was conducted in compliance with the ethical principles of the Declaration of Helsinki, Good
115 Clinical Practice (GCP) ordinance, etc., and registered in a jRCT at the initiation of the study
116 (jRCT2071210081).

117

118 **Trial procedure**

119 This study used KD-414 with 10 µg/dose of the active ingredients (converted to total protein amount)
120 which was manufactured following good manufacturing practice (GMP) standards for investigational
121 new drugs in Japan. A total of three vaccinations were administered for the primary series: two
122 intramuscular vaccinations of KD-414 at an interval of 28 days followed by one intramuscular
123 vaccination administered 13 weeks after the second vaccination. The original plan was to administer
124 two doses at the start of this study. However, the plan was revised, and three doses were administered
125 for the primary series during this study based on the results of the preceding phase 1/2 study. The
126 change in the protocol was explained to all participants continuing on the study to obtain informed
127 consent. The third vaccination was administered to participants who wished to receive the third
128 vaccination among those who gave written informed consent.

129 Each participant recorded his/her health status and body temperature in an e-diary during the period
130 beginning after each vaccination with KD-414 to day six after vaccination (a total of seven days,
131 including the day of vaccination). The participants underwent a follow-up examination 28 days after
132 the third vaccination. After completion of the follow-up examination, the participants entered a one-
133 year follow-up period. participants who did not receive the second or third vaccination also entered a
134 one-year follow-up period after the last vaccination.

135 For immunogenicity evaluation, up to 100, 50, 50, 50, and 50 participants were allocated to the
136 immunogenicity analysis subjects by age groups of 18 - 29 years, 30 - 39 years, 40 - 49 years, 50 - 59
137 years, and 60 years or older, respectively, in the order of enrollment at pre-specified medical
138 institutions. In immunogenicity analysis subjects, blood was collected before and 28 days after each
139 dose and 13, 26, and 52 weeks after the third dose to measure the neutralizing antibody titer against
140 the pseudovirus SARS-CoV-2 (Wuhan).

141

142 Injection site erythema, swelling, induration, and pain, which were observed after administration of
143 each dose of KD-414 up to six days after vaccination, were defined as solicited local adverse events
144 and were generally considered to be related to the investigational product. Fever, headache, malaise,
145 nausea, and myalgia, which were observed after administration of each dose of KD-414 up to six days

146 after vaccination, were defined as solicited systemic adverse events. All events not that could not be
147 characterized as solicited adverse events were recorded as unsolicited adverse events. Adverse events
148 were classified into five grades (grades 0 to 4). The criteria were in accordance with those of the Food
149 and Drug Administration (FDA)¹⁴, however, erythema/redness, induration/swelling, and fever with a
150 severity of less than grade 1 were characterized as grade 0. Among all adverse events, those for which
151 there was at least a reasonable possibility of a relationship with the investigational product that could
152 not be ruled out were defined as adverse reactions.

153

154 The primary endpoint was the geometric mean neutralizing antibody titers (GMTs) of KD-414 against
155 the pseudovirus SARS-CoV-2 (Wuhan) 28 days after the second vaccination and third vaccinations,
156 respectively. As a secondary endpoint, the neutralizing antibody-seroconversion rates 28 days after the
157 second and third vaccination with the investigational product, respectively, were evaluated. The
158 neutralizing antibody-seroconversion rate was defined as the rate of participants whose neutralizing
159 antibody titer increased at least 4-fold compared to that before the first vaccination of the
160 investigational product.

161

162 **Pseudovirus SARS-CoV-2 (Wuhan) spike protein neutralizing antibody titers**

163 The pseudovirus neutralizing antibody assay¹² was performed at LabCorp Drug Development. The
164 pseudovirus neutralizing antibody assay with a lentivirus-based pseudovirus particle expressing the
165 SARS-CoV-2 (Wuhan) spike protein was validated at Monogram Biosciences and then transferred to
166 LabCorp Drug Development. Briefly the mixed pseudoviruses and serially diluted serum samples were
167 incubated in HEK293 cells expressing the ACE2 receptor. After incubation, the luciferase produced
168 was measured to determine the pseudovirus neutralizing antibody titers (50% inhibition dose [ID50])
169 using the following calculation formula. The lower limit of quantitation (LLOQ) for pseudovirus
170 neutralizing antibodies was 40 (ID50).

171

$$\% \text{ Inhibition} = 100\% - \left(\frac{\text{RLU (Vector + Sample + Diluent)} - \text{RLU (Background)}}{\text{RLU (Vector + Diluent)} - \text{RLU (Background)}} \right) \times 100\%$$

172

$$\% \text{ Inhibition} = 100\% - \left(\frac{\text{RLU (Vector + Sample + Diluent)} - \text{RLU (Background)}}{\text{RLU (Vector + Diluent)} - \text{RLU (Background)}} \right) \times 100\%$$

173

174 **Statistical Analysis**

175 The target sample size for this study was set to 2000 participants to evaluate the safety profile of KD-
176 414. Since this was an exploratory study, no hypothesis testing was performed with statistically
177 powered sample sizes. Therefore, no adjustment for the multiplicity of type I errors was performed. In
178 all the analyses, missing data were not imputed.

179 Safety analyses were performed for the KD-414-vaccinated population with evaluable safety data. The
180 number of participants and incidence of solicited local adverse reactions, solicited systemic adverse
181 reactions, and unsolicited adverse reactions were calculated.

182 Immunogenicity analysis was performed in the full analysis set (FAS) and per-protocol set (PPS). The
183 results of the PPS analysis were handled as the primary results. The FAS involved the population of
184 participants vaccinated with KD-414 among the immunogenicity analysis subjects, excluding those
185 without data on neutralizing antibody titers after investigational product vaccination and those with
186 deviation from GCP. PPS was defined as the population in which participants with major deviations
187 from the protocol (related to the inclusion criteria, dosage and administration, prohibited concomitant
188 medications/therapies, and timing of blood collection) were excluded from the FAS. For the primary
189 evaluation, the GMTs were analyzed 28 days after the second and third vaccination, respectively, and
190 the 95% CI was calculated based on the t-distribution. For the secondary evaluation, the
191 seroconversion rate of the neutralizing antibody titer and the Clopper-Pearson 95% CI were calculated.

192 In addition, subgroup analyses were performed according to the age group.

193 For other demographic characteristics factors, descriptive statistics were calculated for continuous data,
194 and the frequencies and the percentages were calculated for categorical data.

195 SAS Release 9.4 (SAS Institute Inc., Cary, NC, USA) was used for the statistical analysis.

196

197 **Results**

198 **Population**

199 While the target number of participants was 2000, 2500 participants received the first vaccination of

200 the investigational product, and 2474 participants received up to the second vaccination. A total of 150
201 participants discontinued the study after the second vaccination. Of these, 106 participants
202 discontinued the study after they were confirmed to have been infected with SARS-CoV-2, according
203 to the protocol. Written consent was obtained from 2324 participants for changes in protocol for the
204 administration of additional third vaccination. The third vaccination was administered to 2081
205 participants who wished to receive the third vaccination. A total of 243 participants who did not wish
206 to receive the third vaccination proceeded to the follow-up period after the second vaccination.
207 Similarly, of the 295 participants in the immunogenicity analysis subjects, 291 participants received
208 up to the second vaccination, and 249 participants received the third vaccination. None of the 2500
209 participants who received at least one dose of the investigational product were excluded from the
210 safety set. Of the 295 participants in the immunogenicity analysis subjects, 292 participants were
211 included in the FAS, of whom 287 participants were included in the PPS. (Figure 1)

212
213 The mean age of the participants in the safety analysis set was 43.2 years, with no particular preference
214 for sex. The percentage of participants with the underlying diseases was 5.5%. The distributions of
215 age, sex, and underlying diseases in the PPS were also similar. The percentage of participants with a
216 negative neutralizing antibody titer against the pseudovirus SARS-CoV-2 before the first vaccination
217 with the investigational product was 96.5%. (Table 1)

218

219 **Safety**

220 No participants died. Four serious adverse events (SAE) other than death were observed in four
221 participants during the period from after the first vaccination with the investigational product to 28
222 days after the second vaccination with the investigational product and the period from after the third
223 vaccination to 28 days after the third vaccination. The investigator did not consider the SAE to be
224 related to the investigational product. Nine events in seven participants required or should have led to
225 discontinuation of the investigational product (significant adverse events). The investigator considered
226 all significant adverse events related to the investigational product.

227

228 The incidence (number of participants with onset/number of participants in the safety analysis set) of
229 adverse reactions from after the first vaccination to 28 days after the third vaccination of the
230 investigational product in the safety analysis set, in which KD-414 was administered at least once,
231 was 80.6% (2015/2500). The most common adverse reaction was injection site pain. Relatively
232 common adverse reactions with an incidence of 10% or higher included injection site pain, malaise,
233 headache, injection site erythema, myalgia, and injection site induration. When the incidence of
234 adverse reactions was examined based on age, the incidence of solicited systemic adverse reactions
235 was higher in participants aged 18 - 40 years than in participants aged 41 - 64 years or those aged 65
236 years or older. No noteworthy trends was observed in the incidence of adverse reactions in participants
237 with or without underlying diseases. (Table 2)

238 Eleven adverse reactions of high severity (grade 3 or higher) were observed in nine participants. Most
239 adverse reactions were of grade 1 or 2. (Table 3)

240 No differences were observed in the types of adverse reactions associated with first, second and third
241 vaccinations, and no noteworthy tendency was observed with respect to the incidences. (Table 4)

242 From the first vaccination with the investigational product to the completion of the follow-up
243 examination, no case of suspected vaccine-associated enhanced respiratory disease (ERD) or antibody
244 dependent enhancement (ADE) was reported.

245

246 **Neutralizing responses**

247 The GMTs (95% CI) for pseudovirus SARS-CoV-2 28 days after the second and third vaccination of
248 the investigational product were 139.6 (118.9 - 164.0) and 285.6 (244.3 – 334.0), respectively, showing
249 an approximately two-fold increase after the third vaccination compared to that after the second
250 vaccination. The neutralizing antibody-seroconversion rates (95% CI) 28 days after the second and
251 third vaccination were 67.0% (61.2% - 72.5%) and 84.5% (79.3% - 88.9%), respectively. (Table 5)

252

253 Analyses of neutralization GMTs by age subgroups of 18 - 40 years, 41 - 64 years, and \geq 65 years

254 showed that the values were 199.9 (163.6 - 244.4), 103.2 (79.9 - 133.2), and 50.7 (26.5 - 97.1),
255 respectively, 28 days after the second vaccination, and 327.6 (269.8 – 397.9), 272.2 (211.5 - 350.4),
256 and 128.0 (51.6 - 317.7), respectively, 28 days after the third vaccination. (Table 6)

257

258 **Discussion**

259 When intramuscularly administered three times to healthy Japanese participants aged 18 years or older
260 who had no history of both COVID-19 and COVID-19 vaccination including unapproved vaccines, a
261 favorable safety profile of KD-414 (10 µg/dose) was shown. The neutralizing antibody titers against
262 pseudovirus SARS-CoV-2 (Wuhan) increased after the third vaccination. The most frequent adverse
263 reaction was injection site pain, followed by relatively frequent adverse reactions such as malaise,
264 headache, injection site erythema, myalgia, and injection site induration. Most adverse reactions were
265 characterized as grade 1 or 2. A total of 11 grade 3 adverse reactions that prevented daily activities
266 were reported in nine participants, and nine adverse reactions that led to the discontinuation of the
267 following vaccination were reported in seven participants. Many grade 3 adverse reactions and adverse
268 reactions leading to discontinuation of the following vaccination have resolved or have become less
269 severe, and some are still under the follow-up observation. No deaths or serious adverse events with
270 causal relationships were reported. The incidences of solicited local adverse reactions and fever after
271 the third vaccination with KD-414 were similar to those of approved inactivated vaccines used
272 worldwide, mainly in China (BBIBP-CorV, CoronaVac)^{15, 16}, and suggesting that the incidence may
273 be relatively lower than those of approved mRNA vaccines which are currently mainly being used in
274 Japan (Comirnaty, Spikevax)^{3, 4}, which were registered in the WHO Emergency Use Listing Procedure
275 (EUL)¹.

276 In addition, no noteworthy trends were observed in the types and incidences of adverse reactions
277 depending on the number of vaccinations of KD-414. In case that periodical COVID-19 vaccinations
278 will be needed in the future, it should be more favorable for public health to be able to choose useful
279 vaccines produced by several modalities having the profiles like low incidence of adverse reactions
280 and no increase of adverse reactions depending on number of dosing. Since the number of enrolled

281 participants with underlying diseases predetermined in this study protocol was small, further
282 investigation on the safety profile of KD-414 in the specific population is necessary. Although the data
283 is limited in this study, since no particular trend was observed in the incidence of adverse reactions
284 depending on the presence or absence of underlying diseases, KD-414 is expected to be safe for that
285 persons with underlying disease. Currently in Japan, only mRNA vaccine is available for children
286 under five years of age. In addition, approved mRNA vaccines can be administered to pregnant women
287 only when the benefits outweigh their risks. On the other hand, KD-414 has typically demonstrated
288 relatively few adverse reactions, including those of grade 3 or higher. In this sense, KD-414 is expected
289 to be more safely for children and pregnant women. In the future, it is necessary to evaluate safety of
290 KD-414 in the aforementioned populations.

291

292 For immunogenicity, the product H (10 µg/dose) of KD-414 that induced the highest neutralizing
293 antibody titers was selected for the subsequent phases based on the results after the second vaccination
294 of KD-414 in the phase 1/2 study. However, although the preventive effect of the novel corona vaccine
295 against the onset has been shown to correlate highly with the neutralizing antibody level, the threshold
296 of the neutralizing antibody titers required for prevention has not yet been established. Therefore, it is
297 important to evaluate the administration regimen of the three doses of KD-414, in which a higher
298 neutralizing antibody titer can be expected. Therefore, the safety and immunogenicity of the three
299 doses were evaluated in a phase 2/3 study using the administration method in which the third dose is
300 administered three months after the second dose as the primary series. The results showed that GMTs
301 increased by approximately two-folds 28 days after the third investigational product vaccination as
302 compared with that 28 days after the second vaccination, and the extent of increase was similar to that
303 observed after the third vaccination at 6 months after the second vaccination in the phase 1/2 study ¹².
304 The persistence of neutralizing antibody titers after the third vaccination is currently being evaluated
305 in a phase 2/3 study. Analysis of GMTs by age group has shown that the tendency of reduction in the
306 neutralizing antibody titers in the elderly was observed with KD-414, similar to the previously
307 approved vaccines for SARS-CoV-2 ^{17, 18}.

308

309 Currently, no surrogate marker has been established to evaluate the vaccine efficacy against COVID-
310 19 , and the method of measurement of neutralizing antibody titers differs among studies. Therefore,
311 it is difficult to directly compare its efficacy with that of other vaccines. With reference to the literature
312 that reported the vaccine efficacy (VE) of Vaxzevria (the active comparator in the currently ongoing
313 pivotal phase 3 study examining KD-414) against the original strain, which was estimated from the
314 neutralizing antibody titer level ¹⁹, we obtained the international standard units (IU) converted value
315 of neutralization GMTs against pseudovirus SARS-CoV-2 (Wuhan) using the same method as in the
316 literature, and attempted to estimate the VE of KD-414 against the original strain of SARS-CoV-2
317 after vaccination. The results shows that the KD-414 IU converted values of GMTs after the second
318 and third vaccination in participants aged 18 - 40 years were 29.1 IU/mL and 47.8 IU/mL, respectively
319 (Table 6). VE was estimated to be about 70% to 80%, respectively, suggesting that the efficacy of KD-
320 414 could be comparable to that of the approved vaccines. In the future, based on the idea of
321 rebalancing proposed by ICMRA ²⁰, the efficacy of KD-414 is planned to be confirmed by verifying
322 the superiority of immunogenicity to that of Vaxzevria in the ongoing pivotal phase 3 study.

323

324 In addition, it is necessary to examine the cross-reactivity of neutralizing antibody responses elicited
325 by KD-414 vaccination against SARS-CoV-2 variants, and SARS-CoV-2 -specific cellular immune
326 response. As a limitation of this study, the elevation of antibody titers as a results of asymptomatic
327 infection was not fully excluded under the COVID-19 outbreak status. In addition, the cellular immune
328 response by KD-414 vaccination will be evaluated in the currently ongoing phase 3 study in due course.
329 The cross-reactivity of neutralizing antibody responses to SARS-CoV-2 variants and the incidence
330 rate of COVID-19 infection after KD-414 dosing are currently being accumulated.

331

332 The aforementioned reports support the progress of the next phase of clinical studies on KD-414. The
333 three-dose regimen with KD-414 as the primary vaccination is expected to provide good safety and
334 induce high neutralizing antibody titers, especially in the age group of 18 to 40 years. Currently, phase

335 3 (jRCT2031210679) trial with adults aged 18 to 40 years is ongoing to verify the efficacy of three
336 vaccinations with KD-414 as the primary vaccination. In addition, a phase 2/3 study
337 (jRCT2031220032) in children aged ≥ 6 months to < 18 years is ongoing to evaluate the safety and
338 immunogenicity of KD-414.
339

340 **ACKNOWLEDGEMENT**

341 This study was funded by Japan Agency for Medical Research and Development (21nf0101622h0002)
342 and Pharmaceutical Development Support Center.

343 We thank the Institute of Medical Science, the University of Tokyo which provided a virus strain
344 (SARS-CoV-2/UT-HPCo-038/Human/2020/Tokyo).

345 We also thank all the participants who volunteered for this study.

346

347 **AUTHOR CONTRIBUTIONS**

348 KK, KI, MT, and YM designed and coordinated this clinical trial. HN and YO advised technical
349 expertise. KS and ME managed the investigational drug manufacturing and the neutralizing antibody
350 assay. SN, KH, KA, YS, and YI managed and analyzed the data of this study. KU contributed to the
351 clinical trial as a medical expert. KK wrote the first draft manuscript, and YS and TM wrote, reviewed
352 and edited. All authors reviewed and approved the final version. All authors had full access to all the
353 data in the study and had final responsibility for the decision to submit for publication.

354

355 **CONFLICT OF INTEREST**

356 All authors, except for Yuji Sasagawa, Yasuhiro Iwama, and Kohji Ueda, are employees of KM
357 Biologics Co., Ltd.

358 Yuji Sasagawa and Yasuhiro Iwama are employees of Meiji Seika Pharma Co., Ltd., co-developer of
359 KD-414.

360 Kohji Ueda received a fee from KM Biologics Co., Ltd., for the implementation of this study.

361

362 **References**


- 363 1. WHO Emergency use listing (EUL) / Covid-19 Vaccines.
364 <https://www.who.int/teams/regulation-prequalification/eul/covid-19> (accessed Sep 21, 2022).
- 365 2. World Health Organization. WHO coronavirus disease (COVID-19) dashboard.
366 <https://covid19.who.int/> (accessed Sep 21, 2022).
- 367 3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2
368 vaccine. *N Engl J Med* 2021; 384: 403-16.
- 369 4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19
370 vaccine. *N Engl J Med* 2020; 383: 2603-15.
- 371 5. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19
372 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled
373 trials in Brazil, South Africa, and the UK. *Lancet* 2021; 397: 99-111.
- 374 6. Janssen Biotech. Janssen Ad26.COVS.S vaccine for the prevention of COVID-19. FDA briefing
375 document. Presented at the Vaccines and Related Biological Products Advisory Committee
376 Meeting, February 26, 2021 (<https://www.fda.gov/media/146217/download>).
- 377 7. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the
378 United States and Mexico. *N Engl J Med* 2022; 386: 531-43.
- 379 8. Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA COVID-
380 19 Vaccination. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html>.
381 (accessed Sep 21, 2022).
- 382 9. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of
383 Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-
384 19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on
385 Immunization Practices — United States, July 2021. *MMWR Morb Mortal Wkly Rep*. 2021
386 Aug 13; 70(32): 1094-99.
- 387 10. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1
388 nCov-19 Vaccination. *N Engl J Med* 2021; 384: 2092-2101.

- 389 11. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after
390 ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021; 384: 2124-30.
- 391 12. Tanishima M, Ibaragi K, Kido K, et al. Safety and immunogenicity of an inactivated SARS-
392 CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind,
393 placebo-controlled, phase 1/2 clinical study in Japan. *medRxiv* 2022 Jun.
- 394 13. David SK, Deborah C, Arnold R, et al. Neutralizing antibody levels are highly predictive of
395 immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine*. 2021 Jul; 27:
396 1205-11.
- 397 14. U.S. Department of Health and Human Services Food and Drug Administration Center for
398 Biologics Evaluation and Research. Guidance for Industry Toxicity Grading Scale for Healthy
399 Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. September
400 2007.
- 401 15. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2
402 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet*
403 *Infect Dis* 2020; 21: 39-51.
- 404 16. Zhang, Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated
405 SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-
406 controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2021; 21: 181-92.
- 407 17. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019
408 Vaccination. *Clin Infect Dis* 2021; 73, 2065-72.
- 409 18. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older
410 adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-
411 control study. *BMJ* 2021; 374, n2015.
- 412 19. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
413 asymptomatic SARS-CoV-2 infection. *Nature Medicine* 2021; 27: 2032-40.
- 414 20. International Coalition of Medicines Regulatory Authorities. ICMRA COVID-19 Vaccine
415 Development: Future Steps Workshop. June 2021. Available online:

416 <http://www.icmra.info/drupal/en/covid-19/24june2021> (accessed Sep 21, 2022).

417

418 Figure 1: Trial profile



419

420

421

422

423 Table 1: Characteristics of the Participants

Characteristic	Safety analysis set (N=2500)	Per protocol set (N=287)
Age, years	43.2(11.9)	41.0(14.7)
18-40 years	1005(40.2)	148(51.6)
40-64 years	1427(57.1)	125(43.6)
≥65 years	68(2.7)	14(4.9)
Sex		
Male	1200(48.0)	144(50.2)
Female	1300(52.0)	143(49.8)
Underlying disease		
With	2363(94.5)	269(93.7)
Without	137(5.5)	18(6.3)
Baseline anti-SARS CoV-2 neutralizing antibody		
Negative	NA	277(96.5)
Positive	NA	10(3.5)

Data are mean(SD) or n(%).

Underlying disease: such as cardiovascular diseases, renal diseases, hepatic diseases, hematological diseases, developmental disorders, respiratory diseases, or diabetes mellitus.

424

425

426

427

428 Table 2: Adverse reactions within 7 days after the first, second, or third doses.

	Overall (N=2500)	Age			Underlying disease	
		18-40 years (N=1005)	41-64 years (N=1427)	≥65 years (N=68)	With (N=2363)	Without (N=137)
Any adverse reaction	2015(80.6)	-	-	-	-	-
Solicited Injection site adverse reactions within 7 days						
Any	1870(74.8)	774(77.0)	1057(74.1)	39(57.4)	1781(75.4)	89(65.0)
Erythema	407(16.3)	135(13.4)	266(18.6)	6(8.8)	391(16.5)	16(11.7)
Swelling	233(9.3)	78(7.8)	152(10.7)	3(4.4)	218(9.2)	15(10.9)
Induration	261(10.4)	81(8.1)	172(12.1)	8(11.8)	245(10.4)	16(11.7)
Pain	1810(72.4)	760(75.6)	1014(71.1)	36(52.9)	1727(73.1)	83(60.6)
Solicited systemic adverse reactions within 7 days						
Any	964(38.6)	451(44.9)	493(34.5)	20(29.4)	907(38.4)	57(41.6)
Fever	99(4.0)	65(6.5)	32(2.2)	2(2.9)	96(4.1)	3(2.2)
Headache	470(18.8)	232(23.1)	232(16.3)	6(8.8)	445(18.8)	25(18.2)
Fatigue	634(25.4)	299(29.8)	323(22.6)	12(17.6)	601(25.4)	33(24.1)
Nausea	108(4.3)	56(5.6)	52(3.6)	0(0.0)	102(4.3)	6(4.4)
Muscle pain	300(12.0)	129(12.8)	166(11.6)	5(7.4)	277(11.7)	23(16.8)

429 Data are n(%), representing the total number of participants who had adverse reactions related to vaccination.
430 Underlying disease: such as cardiovascular diseases, renal diseases, hepatic diseases, hematological diseases, developmental
431 disorders, respiratory diseases, or diabetes mellitus.
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454

455 Table 3: Severity of Adverse reactions within 7 days after the first, second, or third doses.

Overall(N=2500)	Grade 0	Grade 1	Grade 2	Grade 3
Solicited Injection site adverse reactions within 7 days				
Any	54(2.2)	1729(69.2)	86(3.4)	1(0.0)
Erythema	392(15.7)	12(0.5)	3(0.1)	0(0.0)
Swelling	182(7.3)	44(1.8)	7(0.3)	0(0.0)
Induration	216(8.6)	37(1.5)	8(0.3)	0(0.0)
Pain	NA	1735(69.4)	74(3.0)	1(0.0)
Solicited systemic adverse reactions within 7 days				
Any	22(0.9)	827(33.1)	108(4.3)	7(0.3)
Fever	79(3.2)	13(0.5)	5(0.2)	2(0.1)
Headache	NA	421(16.8)	47(1.9)	2(0.1)
Fatigue	NA	563(22.5)	68(2.7)	3(0.1)
Nausea	NA	98(3.9)	9(0.4)	1(0.0)
Muscle pain	NA	282(11.3)	17(0.7)	1(0.0)

Data are n/N(%), representing the total number of participants who had adverse reactions related to vaccination.

The severity of adverse events were graded as Grade0, Grade1 (Mild), Grade2 (Moderate), Grade3 (Severe), and Grade4 (Potentially life threatening).

456

457

458

459

460

461 Table 4: Solicited and unsolicited adverse reactions within 7 days after each dose.

	After 1 st dose (N=2500)	After 2 nd dose (N=2474)	After 3 rd dose (N=2081)
Solicited Injection site adverse reactions within 7 days			
Any	1344(53.8)	1407(56.9)	1109(53.3)
Erythema	178(7.1)	214(8.6)	201(9.7)
Swelling	65(2.6)	112(4.5)	115(5.5)
Induration	84(3.4)	125(5.1)	123(5.9)
Pain	1266(50.6)	1346(54.4)	1039(49.9)
Solicited systemic adverse reactions within 7 days			
Any	563(22.5)	526(21.3)	393(18.9)
Fever	43(1.7)	38(1.5)	33(1.6)
Headache	243(9.7)	243(9.8)	159(7.6)
Fatigue	351(14.0)	319(12.9)	269(12.9)
Nausea	48(1.9)	50(2.0)	30(1.4)
Muscle pain	160(6.4)	123(5.0)	90(4.3)
Unsolicited systemic adverse reactions within 28 days			
Any	294(11.8)	225(9.1)	147(7.1)

Data are n(%), representing the total number of participants who had adverse reactions related to vaccination.

462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477

478 Table 5: Geometric mean titers and seroconversion rate to SARS-CoV-2 (Wuhan) pseudovirus
479 induced before first dose and after each dose of KD-414.

SARS-CoV-2 (Wuhan) pseudovirus neutralizing antibody titer				
Time Point	<i>n</i>	GMT (<i>ID</i> ₅₀)	Seroconversion	GMT(IU/mL)
Before 1 st dose	287	21.7[20.6-22.8]	NA	-
Day 28 after 1 st dose	287	26.8[24.3-29.6]	6.6%[4.0-10.1%]	-
Day 28 after 2 nd dose	282	139.6[118.9-164.0]	67.0%[61.2-72.5%]	20.4[17.3-23.9]
Day 28 after 3 rd dose	239	285.6[244.3-334.0]	84.5%[79.3-88.9%]	41.6[35.6-48.7]

480 Geometric mean titers are shown with 95%CI. Seroconversion rates are n/N(%[95%CI]).
481 The *ID*₅₀ GMTs were converted to the WHO international standard units (IU/mL) using the conversion factor "0.1458 (for
482 geometric mean)" determined with the WHO International Standard (20/136).
483 Seroconversion was defined as four-fold titer increase from baseline.
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499

500 Table 6: Geometric mean titers, seroconversion rate, and geometric mean titers converted to the
501 WHO international standard units (IU/mL) induced after second and third doses of KD-414.

502
503

	Day 28 after 2 nd dose				Day 28 after 3 rd dose			
	<i>n</i>	GMT (ID ₅₀)	Seroconversion rate	GMT (IU/mL)	<i>n</i>	GMT (ID ₅₀)	Seroconversion rate	GMT (IU/mL)
18-40 years	144	199.9[163.6-244.4]	80.6%[73.1-86.7%]	29.1[23.8-35.6]	119	327.6[269.8-397.9]	90.8%[84.1-95.3%]	47.8[39.3-58.0]
41-64 years	124	103.2[79.9-133.2]	54.8%[45.7-63.8%]	15.0[11.6-19.4]	106	272.2[211.5-350.4]	80.2%[71.3-87.3%]	39.7[30.8-51.1]
≥65 years	14	50.7[26.5-97.1]	35.7%[12.8-64.9%]	7.4[3.9-14.2]	14	128.0[51.6-317.7]	64.3%[35.1-87.2%]	18.7[7.5-46.3]

Geometric mean titers are shown with 95%CI. Seroconversion rates are n/N(%[95%CI]).
The ID₅₀ GMTs were converted to the WHO international standard units (IU/mL) using the conversion factor "0.1458 (for geometric mean)" determined with the WHO International Standard (20/136).
Seroconversion was defined as four-fold titer increase from baseline.